Inclusion Criteria:  Participant has been treated for leptomeningeal metastases after intrathecal chemotherapy and/or radiation OR refuses to undergo additional radiation and/or intrathecal chemotherapy Participant must have a Karnofsky performance status (KPS) >= 60 Participant must have a life expectancy of >= 2 months Women of child-bearing potential must have negative serum pregnancy test and agree to use a reliable form of birth control prior to study entry and for at least two months following study treatment. Male research participants must agree to use a reliable form of birth control and not donate sperm during the study and for at least two months following study treatment Participant has a histologically confirmed EGFRvII+ (epidermal growth factor receptor) tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50) Participant or legal guardian must have the ability to understand and the willingness to sign a written informed consent  Exclusion Criteria:  Research participant requires supplemental oxygen to keep saturation greater than 95% Research participant requires dialysis Research participant has uncontrolled seizure activity and/or clinically evident progressive encephalopathy Failure of research participant or legal guardian to understand the basic elements of the protocol and/or the risks/benefits of participating in the study. Participant is unwilling to stop treatment with chemotherapy or endocrine therapy and/or radiation one week prior and during the first 4 cycles of the study Participant has ventriculoperitoneal shunt Participant has a coagulopathy or bleeding disorder Participant is HIV+ (human immunodeficiency virus) or has acute CMV (cytomegalovirus) infection Participant has any uncontrolled illness, including ongoing or active infection; participant has known active hepatitis B or C infection; participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections Participant has an autoimmune disease that requires constant treatment Participant has another active malignancy Participant is unable to undergo a brain magnetic resonance imaging (MRI) Participant is pregnant or breast feeding